Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

>>yes wouldn't it be great if they could get away with a reasonable size single arm trial (narmafot + standard chemo, sample needs to be much more than n=50) which is then compared to historical control data rather than having to waste effort and $$$ on a randomised control trial to just repeat control information which we already know.
>>There is now so much robust reliable current published data from the pancreatic cancer chemo trials like gem + abraxane and folfirinoc that could be used as the comparator, it would save much time and resources. Ton more efficient, just don't know if the FDA ready to buy something like this!